Biocept Inc (NASDAQ:BIOC) shares rose 6.3% during mid-day trading on Friday . The stock traded as high as $0.36 and last traded at $0.34. Approximately 5,239,687 shares changed hands during mid-day trading, an increase of 98% from the average daily volume of 2,640,951 shares. The stock had previously closed at $0.32.
Separately, Zacks Investment Research lowered shares of Biocept from a “buy” rating to a “hold” rating in a research report on Thursday, January 18th.
The company has a debt-to-equity ratio of 0.24, a current ratio of 1.41 and a quick ratio of 1.27. The firm has a market cap of $21.84, a P/E ratio of -0.39 and a beta of 1.74.
TRADEMARK VIOLATION WARNING: This report was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3299581/biocept-bioc-stock-price-up-6-3.html.
Biocept Company Profile
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.